Peritoneal carcinomatosis of colorectal origin. Current treatment. Review and update;Carcinomatosis peritoneal de origen colorrectal. Estado actual del tratamiento. Revisión y puesta al día

Revista Espanola de Enfermedades Digestivas

Volumn 97, Issue 10, 2005, Pages 716-737

  Gomez Portilla A ^a,b   Cendoya, I ^a   Lopez De Tejada I ^a   Olabarria I ^a   Martinez De Lecea C ^a   Magrach, L ^a   Gil, A ^a   Echevarria J ^a   Valdovinos, M ^a   Larrabide, I ^a  

^a Peritoneal Carcinomatosis Programme   (Spain)

^b Programa Carcinomatosis Peritoneal   (Spain)

Author keywords

Colorectal cancer; Sugarbaker's treatment protocol; Therapeutic approach

Indexed keywords

CAPECITABINE; CISPLATIN; DOXORUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; RALTITREXED;

CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; HUMAN; INCIDENCE; MEDICAL LITERATURE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; REVIEW;

EID: 33748319418     PISSN: 11300108     EISSN: 11300108     Source Type: Journal    
DOI: 10.4321/S1130-01082005001000005     Document Type: Review

References (112)

1. Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis. Comparison of concomitant vs. delayed management. Dis Colon Rectum 2000; 43 (10): 1341-8.
2. Gómez Portilla A. Tratamiento quirúrgico de la carcinomatosis peritoneal de origen colorrectal. Cir Esp 2004; 75 (3): 156.
3. Bottomley A. Metastatic colorectal cancer: treatment challenges and quality of life. Lancet 2002; 359 (4): 1537-8.
4. Ortiz Hurtado H. Tratamiento quirúrgico y resultados del cáncer de colon. Presentación. Cir Esp 2003; 73: (1): 1.
5. Kindler HL, Shulman Kl. Metastatic colorectal cancer. Current Treatment Options in Oncology 2001; 2: 459-71.
6. De Bree E, Witkamp A, Zoetmulder FAN. Intraperitoneal chemotherapy for colorectal cancer. Review article. J Surg Oncol 2002; 79: 46-61.
7. Glehen O, Kwiatkoski M, Sugarbaker PH, Elis D, Levine EA, Gilly FN, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer. A multi-institutional study of 506 patients. ASCO, 2004; January: 22-4.
8. Glehen O, Kwiatkoski M, Sugarbaker PH, Elias D, Levine EA, Gilly FN, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer. A multi-institutional study of 506 patients. J Clin Oncol 2004; 22 (3): 284-329.
9. Sticca RP. Peritoneal carcinomatosis: a final frontier. Ann Surg Oncol 2003; 10 (5): 484-5.
10. Gunderson LL, Sosin H, Levitt S. Extrapelvic colon areas of failure in a reoperation series: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1985; 11: 731-41.
11. Brodsky JT, Cohen AM. Peritoneal seeding following curative resection of colonic carcinoma: implication for adjuvant therapy. Dis Col Rectum 1991; 34: 723-7.
12. Alonso O, Sugarbaker PH. Adult respiratory distress syndrome occurring in two patients undergoing cytoreductive surgery plus perioperative intraperitoneal chemotherapy. Case reports and a review of the literature. Am Surg 2000; 66: 1032-6.
13. Sampson JA. Implantation peritoneal carcinomatosis of ovarian origin. Am J Pathol 1931; 7: 423-43.
14. Chu DZJ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in non-gynecological malignancy: a prospective study of prognostic factors. Cancer 1989; 63: 364-7.
15. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivpoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecological malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88: 358-63.
16. Esquivel J, Angulo F, Bland RK, Stephens AD, Sugarbaker PA. Hemodynamic and cardiac function parameters during heated intraoperative intraperitoneal chemotherapy using the open "coliseum technique". Ann Surg Oncol 2000; 7 (4): 296-300.
17. Scoggins CR, Meszoley IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients wit stage IV disease. Ann Surg Oncol 1999; 6 (7): 651-7.
18. Blair SL, Chu DZJ, Schwartz RE. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from non-gynecological cancer. Ann Surg Oncol 2001; 8 (8): 632-7.
19. Pilati P, Rossi CR, Mocellin S, Foletto M, Scagnet B, Pasetto L, et al. Multimodal treatment of peritoneal carcinomatosis and sarcomatosis. Eur J Surg Oncol 2001; 27: 125-34.
20. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999; 43 (Supl.): S15-S25.
21. Jayne DG, Fook S, Loi C, Seow-Choen F. Pritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89: 1545-50.
22. Witkamp AJ, De Bree E, Van Goethem AR, Zoetmulder FAN. Antitumor treatment. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treatment Reviws 2001; 27: 365-174.
23. Willet CG, Tepper JE, Cohen AM, Orlow E, Welch CE. Failure patterns following curative resection of colonic carcinoma. Surgery 1984; 200 (6): 685-90.
24. Massacesi C, Pistilli B, Valeri M, Lippe P, Rocchi MBL, Cellerino R, et al. Predictors of short- term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil based regimens. Am J Clin Oncol 2002; 25 (2): 140-8.
25. Anonymous: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced colorectal cancer meta-analysis project. J Clin Oncol 1992; 10: 896-903.
26. Anonymous: Efficacy of intravenous continuous infusion of 5-fluorouracil comapared with bolus administration in advanced colorectal cancer: Meta-analysis group in cancer. J Clin Oncol 1998; 16: 301-8.
27. Levy-Piedbois C, Durand-Zaleski I, Juhel H, Schmitt C, Bellanger A, Piedbois P. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann Oncology 2000; 11 (2): 157-61.
28. Calvo E, Cortés J, González-Cao M, Rodríguez J, Aramendia JM, Fernández-Hidalgo O, et al. Combined irinotecan, oxaliplatin and 5-flourouracil in patients with advanced colorectal caner. A feasibility pilot study. Oncology 2002; 63: 254-65.
29. Anonymous: oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5- flourouracil pretreated colorectal cancer. B J Cancer 2001; 85: 1258-64.
30. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
31. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, et al. Phase II study of capecitabine and oxaliplatin in first and second line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 7: 1759-66.
32. Bliberg H, Hendlisz A. Advanced colorectal cancer treatment in Europe: what have we achieved? Review Paper. Anti-Cancer Drugs 2002; 13: 461-71.
33. Meropol NJ, Niedzwiecki D, Hollis D, Schilsky RL, Mayer RJ. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer 2001; 91 (7): 1256-63.
34. Van Custem E, Twelves Ch, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer. Xeloda Colorectal Cancer Study Group. Results of a large phase III study. J Clin Oncol 2001; 19: 4097-106.
35. De Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. A French Intergroup study. J Clin Oncol 1997; 15: 808-15.
36. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. Aprospective randomized comparasion of continuous infusion fluorouracil with conventional bolus schedule in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7: 425-32.
37. Anonymus: Efficacy of intravenous continuous infusion of 5-fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis group in cancer. J Clin Oncol 1998; 16: 301-8.
38. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-14.
39. Douillard JY, Cunningham D, Roth AD, Navarro M, Karasek P, Jandik P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line tretament for metastatic colorectal cancer. A multicenter randomised trial. Lancet 2000; 355: 1041-7.
40. Tsavaris N, Kosmas Ch, Vadiaka M, Koufos Ch. Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-fluorouracil/leucovorin chemotherapy. BMC Cancer 2002; 2 (1): 2-15.
41. Grávalos Castro C, Pérez Escutia MA. Tratamiento adyuvante del cáncer colorrectal. Cir Esp 2003; 73 (1): 38-45.
42. Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimen in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002; 359: 1555-63.
43. Yonemura Y, Fujimura T, Fushida S, Takegawa S, Kamata T, Katayama K, et al. Hypoerthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination. World J Surg 1991; 15 (4): 530-6.
44. Gertsch P. A historical perspective on colorectal liver metastases and peritoneal carcinomatosis: similar results, different treatments. Surg Oncol Clin N Am 2003; 12: 531-41.
45. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon's role. Langenbeck's Arch Surg 1999; 384: 576-87.
46. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221: 29-42.
47. Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am 2003; 12: 703-27.
48. Yonemura Y. Principles of the treatment of peritoneal dissemination. In: Yonemura Y, eds. Peritoneal dissemination-molecular mechanisms and the latest therapy. Kanazawa: Maeda Shoten Co, Ltd; 1998. Chapter 11, p. 175-90.
49. Sugarbaker PH. It's what the surgeon doesn't see that kills the patient. Nippon Med Sch 2000; 67 (1): 5-8.
50. Dubé P, Lasser Ph, Elias D. Traitement de la carcinose peritoneale dórigine colorectal. J Chir (Paris) 1997; 134 (5-6): 233-6.
51. Elias DM, Pocard M. Treatment and prevention of peritoneal carcinomatosis from colorectal cancer. Surg Oncol Clin N Am 2003; 12: 543-59.
52. Gilly FN. Rationale for peritonectomy and perioperative intraperitoneal chemotherapy. Peritoneal Surface Malignancy. Third Biannual Masterclass in Peritoneal Surface malignancy. Basingstoke, Dic 2002.
53. Weissberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA 1955; 159: 1704-7.
54. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale drug administration in the treatment of ovarian cancer. Cancer Tret Rep 1978; 62: 1-9.
55. Katz MH, Barone RM. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am 2003; 12: 673-88.
56. Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arc Surg 2003; 138: 26-33.
57. Sugarbaker PH, Gianola FJ, Speyer JL, Wesley R, Barofsky I, Myers CE. Prospective, randomized trial of intravenous versus intraperitoneal 5- fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 1985; 98: 414-21.
58. Gilly FN, Sayag AC, Carry PY, Brillon G, Roche M, James I, et al. Chimio- hyperthermie intra-peritoneale (CHIP) dans le traitament des carcinoses peritoneales dórigine digestive. Rapport d'une observation et données physiopathologiques. J Chir (París) 1990; 127 (2): 95-8.
59. Fujimoto S, Shrestha RD, Kokubun M, Ohta M, Takahashi M, Kobayashi K, et al. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 1988; 208: 36-41.
60. Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion either mitomycine C. Cancer 1988; 61: 232-7.
61. Elias D, Dube P, Bonvalot S, Meshaka P, Manai M, Cavalcanti A, et al. Treatment of liver metastases with moderate peritoneal carcinomatosis by hepatectomy and cytoreductive surgery follow-ed by immediate postoperative intraperitoneal chemotherapy: feasibility and preliminary results. Hepatogastroenterol 1999; 46: 360-3.
62. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 2003; 12: 689-801.
63. Shido A, Ohmura S, Yamamoto K, Konayashi T, Fujimura T, Yonemura Y. Does hyperthermia induce peritoneal damage in continuous hyperthermic peritoneal perfusion? World J Surg 2000; 24 (5): 507-11.
64. Spratt JS, Adcock RA, Sherill W, Travathen S. Hyperthermic peritoneal perfusion system in canines. Cancer Res 1980; 40: 253-5.
65. Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980; 40: 2563-5.
66. Stuart OA, Stephens AD, Welch L, Sugarbaker PH. Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C. Ann Surg Oncol 2002; 9 (2): 186-91.
67. Fujimoto S, Shrestha RD, Kokubun M, Kobayashi K, Kiuchi S, Ohta M, et al. Pharmacokinetic analysis of mitomycin C for intraperitoneal hyperthermic perfusion in patients with far-advanced or recurrent gastric cancer. Reg Cancer Treat 1989; 2: 198-202.
68. Gan To Kagaku Ryoho. 1989;16 (7): 2411-5. Japanese.
69. Panteix G, Guillaumont M, Cherpin L, Cuichard J, Gilly FN, Carry PY, et al. Study of the pharmacokinetics of mitomycin C in humans during intraperitoneal chemothermia with special mention of the concentration in local tissues. Oncology 1993; 50: 366-70.
70. Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5- fluorouracil: pharmacokinetic studies. Oncology 1998; 55 (2): 130-8.
71. Elias D, El Otmany A, Bonnay M, Pci A, Ducreux M, Antoun S, et al. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology 2002; 63: 346-52.
72. Elias DM, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am 2003; 12: 755-69.
73. Elias DM, Pocard M. Treatment and prevention of peritoneal carcinomatosis from colorectal cancer. Surg Oncol Clin N Am 2003; 12: 543-59.
74. Wientjes MG, Badalament RA, Wang RC, Hassan F, Au JL. Penetration of mitomycin C in human bladder. Cancer Res 1993; 53: 3314-31.
75. Glehen O, Gilly FN. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am 2003; 12: 649-71.
76. Gómez Portilla A, Sugarbaker PH. Segunda cirugía (second look) después de citorreducción y quimioterapia intraperitoneal en la carcinomatosis por cáncer colorrectal: análisis de factores pronósticos. Cir Esp 1997; 61: 240-5.
77. Gómez Portilla A, Deraco M, Sugarbker PH. Clinical pathway for peritoneal carcinomatosis from colon and rectal cancer: guidelines for current practice. Tumori 1997; 83 (Supl.): 725-8.
78. Gómez Portilla A, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognosis features. World J Surg 1999; 23: 23-9.
79. Jacquet P, Stephens AD, Averbach AM, Chang D, Ettinghausen SE, Dalton RR, et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996; 77: 2622-9.
80. Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 1993; 113: 631-6.
81. Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic heated intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999; 6: 790-6.
82. Dromain C, Bisdorff A, Elias D, Antoun S, Boige V, Lasser P, et al. Computed tomographic features of peritoneal carcinomatosis treated by intraperitoneal chemohyperthermia. J Comput Assist Tomogr 2003; 27 (3): 327-32.
83. Loggie BW, Fleming RA. Complications of heated intraperitoneal chemotherapy and strategies for prevention. Cancer Treat Res 1996; 82: 221-33.
84. McQuellon RP, Loggie BW, Lehman AB, Russell GM, Fleming RA, Shen P, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003; 10 (2): 155-62.
85. Horsell KW, Merten S, Clingan P, King DW, Morris DL. Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer. Aust N Z J Surg 1999; 69 (10): 729-32.
86. Witkamp AJ, de Bree E, Kaag MM, Van Slooten GW, Van Coervorden F, Zoetmulder FAN. Extensive surgical cytoreduction and intra-operative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001; 88: 458-63.
87. Witkamp AJ, de Bree E, Kaag MM, Boot H, Beijnen JH, van Slooten GW, et al. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis from colorectal origin. Eur J Cancer 2001; 37: 979-84.
88. Yamaguchi A, Tsukoika Y, Fushida S, Kurosaka Y, Kanno M, Yonemura Y, et al. Intraperitoneal hyperthermic treatment for peritoneal dissemination of colorectal cancers. Dis Colon Rectum 1992; 35 (10): 964-8.
89. Schneebaum S, Arnold MW, Staubus A, Young DC, Dumond D, Martin EW Jr. Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Ann Surg Oncol 1996; 3: 44-50.
90. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1996; 6 (8) : 727-31.
91. Cavaliere F, Perri P, Di Filippo F, Giannarelli D, Botti C, Cosimelli M, et al. Treatment of peritoneal carcinomatosis with intent of cure. J Surg Oncol 2000; 74: 41-4.
92. Elias D, Dubé P, Blot F, Bonvallot S, Eggenspieler P, Sabourin JC, et al. Peritoneal carcinomatosis treatment with curative intent: the Institute Gustave-Roussy experience. Eur J Surg Oncol 1997; 23: 317-21.
93. Elias D, Gachot B, Bonvallot S, Blot F, Sabourin JC, Ducreux M, et al. Carcinoses peritoneales traitees par exerese complete et chimiotherapie intra-peritoneale postoperatoire immediate (CIPPI). Etude de phase II portant sur 54 malades. Gastroenterol Clin Biol 1997; 21: 181-7.
94. Elias D, Antoun S, Raynard B, Puizillout JM, Sabourin JC, Ducreux M, et al. Traitement des carcinoses peritonelaes par exerese complete et chimiohyperthermie intraperitoneale. Etude de phase I-II permettant de definir la meilleure procedure technique. Chirurgie 1999; 124: 380-9.
95. Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001; 92: 71-6.
96. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surgeon 2000; 66: 561-8.
97. Fujimura T, Yonemura Y, Fujita H, Michiwa Y, Kawamura T, Nojima N, et al. Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intra-abdominal malignancies. Int Surg 1999; 84 (1): 60-6.
98. Beaujard AC, Glehen O, Caillot JL, Francois Y, Bienvenu J, Pantiex G, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract caner patients with peritoneal carcinomatosis. Cancer 2000; 88 (11): 2512-9.
99. Piso P, Bektas H, Werner U, Schlitt HJ, Kubicka S, Bornscheuer A, et al. Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. Eur J Surg Oncol 2001; 27: 286-90.
100. Rey Y, Porcheron J, Talabard JN, Szanfnicki K, Balique JG. Carcinoses peritoneales traitees par chirurgie de reduction tumorale et chimiohyperthermie intraperitoneale. Ann Chir 2000; 125: 631-42.
101. Porcheron J, Talabard JN, Breton C, Szafnicki K, Luxembourger O, Dufraisse G, et al. Intraperitoneal chemohyperthermia for peritoneal carcinomatosis: original modelling, clinical tolerance and results study about 30 patients. Hepatogastroenterology 2000; 47: 1411-8.
102. Vaira M, Scuderi S, Castamagna D, Barone R, Aemo B, Mioli PR, et al. Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis. Minerva Chir 2002; 57 (5): 579-605.
103. Shen P, Levine EA, Hall J, Case D, Russell G, Fleming RA, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003; 138: 26-33.
104. Pilati P, Mocellini S, Rossi CR, Foletto M, Campana L, Nitti D, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol 2003; 10 (5): 508-13.
105. Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch Ph, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003; 21 (5): 799-806.
106. Sugarbaker Ph, Jablonski KA. Prognostic features of 51 colorectal and 130 appendicel cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995; 221: 124-32.
107. Sugarbaker PH, Schellinx MET, Chang D, Koslowe P, Von Meyerfeldt M. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 1996; 20: 585-92.
108. Zoetmulder FAN, Verwaal V. Hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C significantly improves survival in patients with peritoneal carcinomatosis of colorectal origin (abstract) ASCO Prog Proc 2002; 21: 147a.
109. Zoetmulder FAN. Prevention and treatment of carcinomatosis from colon cancer. Peritoneal Surface Malignancy. Third Biannual Masterclass in Peritoneal Surface Malignancy. Basingstoke Dic 2002.
110. Zoetmulder FAN. Hyperthermic intrapoeritoneal chemotherapy in peritoneal carcinomatosis. XXXVIII Congress of the European Society for Surgical Research, Ghent, Belgium May. 2003.
111. Verwaal VJ, Van Ruth S, De Bree E, Van Slooten GW, Van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-43.
112. Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P. Extra-hepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg 2003; 90 (5): 567-74.